Sanofi to exam cancer-starving devalue in China in 2013

<p>HONG KONG (Reuters) – <span>Sanofi-Aventis</span> skeleton to start contrast a novel devalue that is designed to starve <span>liver cancer</span> to genocide in a proviso one tellurian clinical hearing in <span>China</span> and presumably South Korea in 2013.</p>
<p> The compound, called slit-trap, was grown by a Chinese collaborator, <span>Shanghai Institutes of Biological Sciences</span>, and will shortly be prepared for a “first-in-man” trial.</p>
<p> “It is now in pre-clinical (stage) and is going into hospital early subsequent year,” pronounced arch executive officer <span>Christopher Viehbacher</span> in an talk in Hong Kong.</p>
<p> The personalized therapy is tailored for a certain form of <span>liver cancer patients</span> who have high levels of a protein called slit, that nourishes a expansion and helps it widespread to o...